Literature DB >> 25583879

A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects.

Pascal Bonaventure1, Sujin Yun2, Philip L Johnson2, Anantha Shekhar2, Stephanie D Fitz2, Brock T Shireman2, Terry P Lebold2, Diane Nepomuceno2, Brian Lord2, Michelle Wennerholm2, Jonathan Shelton2, Nicholas Carruthers2, Timothy Lovenberg2, Christine Dugovic2.   

Abstract

Orexins (OXs) are peptides produced by perifornical (PeF) and lateral hypothalamic neurons that exert a prominent role in arousal-related processes, including stress. A critical role for the orexin-1 receptor (OX1R) in complex emotional behavior is emerging, such as overactivation of the OX1R pathway being associated with panic or anxiety states. Here we characterize a brain-penetrant, selective, and high-affinity OX1R antagonist, compound 56 [N-({3-[(3-ethoxy-6-methylpyridin-2-yl)carbonyl]-3-azabicyclo[4.1.0]hept-4-yl}methyl)-5-(trifluoromethyl)pyrimidin-2-amine]. Ex vivo receptor binding studies demonstrated that, after subcutaneous administration, compound 56 crossed the blood-brain barrier and occupied OX1Rs in the rat brain at lower doses than standard OX1R antagonists GSK-1059865 [5-bromo-N-({1-[(3-fluoro-2-methoxyphenyl)carbonyl]-5-methylpiperidin-2-yl}methyl)pyridin-2-amine], SB-334867 [1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea], and SB-408124 [1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea]. Although compound 56 did not alter spontaneous sleep in rats and in wild-type mice, its administration in orexin-2 receptor knockout mice selectively promoted rapid eye movement sleep, demonstrating target engagement and specific OX1R blockade. In a rat model of psychological stress induced by cage exchange, the OX1R antagonist prevented the prolongation of sleep onset without affecting sleep duration. In a rat model of panic vulnerability (involving disinhibition of the PeF OX region) to threatening internal state changes (i.e., intravenous sodium lactate infusion), compound 56 attenuated sodium lactate-induced panic-like behaviors and cardiovascular responses without altering baseline locomotor or autonomic activity. In conclusion, OX1R antagonism represents a novel therapeutic strategy for the treatment of various psychiatric disorders associated with stress or hyperarousal states.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25583879      PMCID: PMC4352589          DOI: 10.1124/jpet.114.220392

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  Defense reaction elicited by injection of GABA antagonists and synthesis inhibitors into the posterior hypothalamus in rats.

Authors:  A Shekhar; J A DiMicco
Journal:  Neuropharmacology       Date:  1987-05       Impact factor: 5.250

2.  The circumventricular organs form a potential neural pathway for lactate sensitivity: implications for panic disorder.

Authors:  A Shekhar; S R Keim
Journal:  J Neurosci       Date:  1997-12-15       Impact factor: 6.167

3.  Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions.

Authors:  A Shekhar; S R Keim; J R Simon; W J McBride
Journal:  Pharmacol Biochem Behav       Date:  1996-10       Impact factor: 3.533

4.  Dorsomedial hypothalamic sites where disinhibition evokes tachycardia correlate with location of raphe-projecting neurons.

Authors:  B C Samuels; D V Zaretsky; J A DiMicco
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-04-08       Impact factor: 3.619

Review 5.  Role of orexin/hypocretin in dependence and addiction.

Authors:  Ruth Sharf; Maysa Sarhan; Ralph J Dileone
Journal:  Brain Res       Date:  2009-08-20       Impact factor: 3.252

6.  Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat.

Authors:  Michel A Steiner; Carla Sciarretta; Catherine Brisbare-Roch; Daniel S Strasser; Rolf Studer; Francois Jenck
Journal:  Psychoneuroendocrinology       Date:  2012-08-20       Impact factor: 4.905

7.  Regulation of anxiety by GABAA receptors in the rat amygdala.

Authors:  S K Sanders; A Shekhar
Journal:  Pharmacol Biochem Behav       Date:  1995-12       Impact factor: 3.533

8.  Neural pathways underlying lactate-induced panic.

Authors:  Philip L Johnson; William A Truitt; Stephanie D Fitz; Christopher A Lowry; Anantha Shekhar
Journal:  Neuropsychopharmacology       Date:  2007-12-05       Impact factor: 7.853

9.  Dorsomedial hypothalamic GABA regulates anxiety in the social interaction test.

Authors:  A Shekhar; J S Katner
Journal:  Pharmacol Biochem Behav       Date:  1995-02       Impact factor: 3.533

Review 10.  Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls.

Authors:  Jiann Wei Yeoh; Erin J Campbell; Morgan H James; Brett A Graham; Christopher V Dayas
Journal:  Front Neurosci       Date:  2014-02-25       Impact factor: 4.677

View more
  19 in total

1.  Optical probing of orexin/hypocretin receptor antagonists.

Authors:  Shi-Bin Li; Natalie Nevárez; William J Giardino; Luis de Lecea
Journal:  Sleep       Date:  2018-10-01       Impact factor: 5.849

Review 2.  The hypocretin/orexin system as a target for excessive motivation in alcohol use disorders.

Authors:  David E Moorman
Journal:  Psychopharmacology (Berl)       Date:  2018-03-06       Impact factor: 4.530

3.  The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice.

Authors:  Marcelo F Lopez; David E Moorman; Gary Aston-Jones; Howard C Becker
Journal:  Brain Res       Date:  2016-02-04       Impact factor: 3.252

4.  Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.

Authors:  Taylor A Gentile; Steven J Simmons; Mia N Watson; Krista L Connelly; Eugen Brailoiu; Yanan Zhang; John W Muschamp
Journal:  Neuropsychopharmacology       Date:  2017-07-25       Impact factor: 7.853

Review 5.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

6.  OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2 -INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES.

Authors:  Philip L Johnson; Lauren M Federici; Stephanie D Fitz; John J Renger; Brock Shireman; Christopher J Winrow; Pascal Bonaventure; Anantha Shekhar
Journal:  Depress Anxiety       Date:  2015-08-19       Impact factor: 6.505

Review 7.  Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.

Authors:  Ying Han; Kai Yuan; Yongbo Zheng; Lin Lu
Journal:  Neurosci Bull       Date:  2019-11-28       Impact factor: 5.203

8.  Hypothalamic orexin's role in exacerbated cutaneous vasodilation responses to an anxiogenic stimulus in a surgical menopause model.

Authors:  Lauren M Federici; Izabela Facco Caliman; Andrei I Molosh; Stephanie D Fitz; William A Truitt; Pascal Bonaventure; Janet S Carpenter; Anantha Shekhar; Philip L Johnson
Journal:  Psychoneuroendocrinology       Date:  2015-12-18       Impact factor: 4.905

Review 9.  Sleep disturbance in PTSD and other anxiety-related disorders: an updated review of clinical features, physiological characteristics, and psychological and neurobiological mechanisms.

Authors:  Anne Richards; Jennifer C Kanady; Thomas C Neylan
Journal:  Neuropsychopharmacology       Date:  2019-08-23       Impact factor: 7.853

10.  Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.

Authors:  Dehui Zhang; David A Perrey; Ann M Decker; Tiffany L Langston; Vijayakumar Mavanji; Danni L Harris; Catherine M Kotz; Yanan Zhang
Journal:  J Med Chem       Date:  2021-06-08       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.